Patrick Heron

Tubulis® generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets.

BlueWater Biosciences is a preclinical stage biotechnology company advancing a novel platform of unimolecular pharmacotherapies to transform the treatment of obesity and associated comorbidities. Our founders bring unparalleled expertise and a relentless drive to lead the next wave of innovative solutions for patients. At BlueWater Biosciences, we are dedicated to creating a healthier future.

Founded in December 2021, SanReno Therapeutics is a clinical-stage biotech focused on kidney diseases and related therapeutic areas. SanReno’s founding investors and partners including Chinook Therapeutics, a leading player in kidney diseases, as well as Pivotal bioVenture Partners China and Frazier Healthcare Partners, both world renown life-science investors. SanReno is committed to the research and development, production and commercialization of drugs in kidney diseases and related therapeutic areas, looks forward to providing innovative clinical solutions to prolong the lives of patients and create a better quality of living for them. Currently, SanReno holds two core assets in the Greater China area and Singapore, including atrasentan (Phase III) and BION-1301 (Phase II).

HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccines. Our initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.

MBX Biosciences, Inc. is a clinical stage biopharmaceutical company pioneering investigational Precision Endocrine Peptides (PEPs™). PEPs are designed to overcome key limitations of native peptide therapeutics to deliver superior pharmacologic properties. MBX is advancing a pipeline of PEP candidates to address the unmet needs of people with endocrine disorders. The company’s lead product candidate, MBX 2109 for the treatment of hypoparathyroidism, is currently in a Phase 1 clinical trial. Members of MBX’s leadership team have collaborated over several decades on the discovery, development, and commercialization of highly successful endocrine therapeutics including Forteo® and Humalog®. The company is supported by leading life science investors including Frazier Life Sciences, New Enterprise Associates and OrbiMed.

Aspen is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical need, beginning with autologous neuron replacement for Parkinson’s disease (PD) and extending across the brain and affected organs.

Mirum Pharmaceuticals is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum combines deep rare disease expertise with strong connections to patient communities. The company’s commercial portfolio includes LIVMARLI® (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM® (cholic acid) for bile-acid synthesis disorders, and CTEXLI® (chenodiol) for cerebrotendinous xanthomatosis (CTX). Mirum’s clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV) and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS). Mirum’s success is driven by a team dedicated to advancing high impact medicines through strategic development, disciplined execution and purposeful collaboration across the rare disease ecosystem. Learn more at www.mirumpharma.com.

Mirum MEA is a borderless digital agency with innovation at its core. Active throughout the region, our teams work to transform business, design innovative digital experiences, build platforms, augment physical spaces and activate commerce. We blend creativity, content creation, digital design, data, and analytics to make experiences that people enjoy and businesses need. Mirum is part of Wunderman Thompson and the WPP Network.

We are a genetics medicine company based in Philadelphia, PA, a city with a rich history of scientific discovery and medical advancement. As a leading developer of cutting-edge therapeutics for disorders of the central nervous system (CNS), we are proud to be a part of this dynamic research community. We are also excited about our new laboratory at the Princeton West Innovation Campus in Hopewell, New Jersey, which will help us evolve the standard for biotech innovation and development. At Passage Bio, we have a bold vision to fulfill the promise of gene therapy and a differentiated approach to gene therapy development through our collaboration with University of Pennsylvania's Gene Therapy Program and Orphan Disease Center. Our deep pipeline of optimized gene therapies for CNS disorders includes lead programs focused on the following devastating diseases: GM1 gangliosidosis Krabbe disease Frontotemporal dementia

Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in the OPUS Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages the Company’s carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in the Company’s PCV franchise. Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF®, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to develop high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella.

Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in the OPUS Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages the Company’s carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in the Company’s PCV franchise. Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF®, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to develop high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella.

Arcutis (Nasdaq: ARQT) was founded in 2016 to address significant unmet needs in medical dermatology. The company is an early commercial stage biopharmaceutical company focused on developing and commercializing best-in-class products. Our strategy is to exploit recent innovations in inflammation and immunology to bring the best molecules to bear against validated physiologic targets known to treat dermatological diseases and disorders. Our management team has extensive expertise in the development and commercialization of medical dermatology products, having held key leadership roles at a number of leading dermatology companies and, collectively, has successfully developed more than 50 FDA-approved products. We believe that by leveraging our team’s unique experience and demonstrated expertise to identify, develop and commercialize best-in-class molecules against validated targets, we will be able to develop differentiated products in less time, at lower cost, and at substantially lower risk than other approaches. Arcutis​ combination of vision, unmet medical need, experienced management and strategic approach has attracted support from leading investors in the life sciences sector.

Iterum Therapeutics plc is an Ireland-based clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives. These products are aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum’s first product is a novel anti-infective compound that has demonstrated potent in-vitro activity vs. a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. For more information on Iterum Therapeutics please visit www.iterumtx.com.

IMAGO BIOSCIENCES LTD is a biotechnology company based out of CHURCH COTTAGE 28 BROADWAY, CHILTON POLDEN, BRIDGWATER, United Kingdom.

Our scientific efforts are aimed at developing drugs that improve the management of proliferative diseases of the bone marrow. Our clinical focus is on acute myeloid leukemia, myelodysplastic syndrome, polycythemia vera, myelofibrosis and essential thrombocythemia. These diseases share several features. They are diseases caused by acquired mutations in blood stem cells. To varying degrees, these mutations drive excessive growth of bone marrow cells, as well as alter their function. For example, myelofibrosis can be viewed as a chronic inflammatory disorder in which inflammatory cytokines and growth factors cause bone marrow cells to alter the architecture of and ultimately destroy the bone marrow. Imago BioSciences has developed inhibitors of the enzyme lysine-specific demethylase 1 (LSD1). This enzyme plays a critical role in regulating the growth and development of bone marrow cells. Our first clinical inhibitor of LSD1, bomedemstat (or IMG-7289) is being studied in patients with acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms including myelofibrosis. Future clinical studies are planned for other related diseases.

Tubulis® generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets.

BlueWater Biosciences is a preclinical stage biotechnology company advancing a novel platform of unimolecular pharmacotherapies to transform the treatment of obesity and associated comorbidities. Our founders bring unparalleled expertise and a relentless drive to lead the next wave of innovative solutions for patients. At BlueWater Biosciences, we are dedicated to creating a healthier future.

Founded in December 2021, SanReno Therapeutics is a clinical-stage biotech focused on kidney diseases and related therapeutic areas. SanReno’s founding investors and partners including Chinook Therapeutics, a leading player in kidney diseases, as well as Pivotal bioVenture Partners China and Frazier Healthcare Partners, both world renown life-science investors. SanReno is committed to the research and development, production and commercialization of drugs in kidney diseases and related therapeutic areas, looks forward to providing innovative clinical solutions to prolong the lives of patients and create a better quality of living for them. Currently, SanReno holds two core assets in the Greater China area and Singapore, including atrasentan (Phase III) and BION-1301 (Phase II).

HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccines. Our initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.

MBX Biosciences, Inc. is a clinical stage biopharmaceutical company pioneering investigational Precision Endocrine Peptides (PEPs™). PEPs are designed to overcome key limitations of native peptide therapeutics to deliver superior pharmacologic properties. MBX is advancing a pipeline of PEP candidates to address the unmet needs of people with endocrine disorders. The company’s lead product candidate, MBX 2109 for the treatment of hypoparathyroidism, is currently in a Phase 1 clinical trial. Members of MBX’s leadership team have collaborated over several decades on the discovery, development, and commercialization of highly successful endocrine therapeutics including Forteo® and Humalog®. The company is supported by leading life science investors including Frazier Life Sciences, New Enterprise Associates and OrbiMed.